Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2025)
Monopar Therapeutics (MNPR) reported Enterprise Value of -$61.8 million for Q4 2025, down 34.96% on a YoY basis from -$95.1 million in Q4 2024, and up 51.57% sequentially from -$127.7 million in Q3 2025.
Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 10 years of Enterprise Value data on file, last reported at -$61.8 million in Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 34.96% year-over-year to -$61.8 million; the trailing twelve-month figure through Dec 2025 stood at -$61.8 million (down 34.96% YoY), and the FY2025 full-year result was -$61.8 million, down 34.96% from the prior year.
- Enterprise Value improved to -$61.8 million in Q4 2025, from -$127.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.5 million in Q3 2023 to a low of -$127.7 million in Q3 2025.
- A 5-year average of -$25.7 million and a median of -$17.1 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value jumped 60.39% in 2023 and tumbled 2020.86% in 2025, its largest moves.
- Tracing MNPR's Enterprise Value over 5 years: stood at -$20.0 million in 2021, then soared by 59.1% to -$8.2 million in 2022, then advanced by 11.24% to -$7.3 million in 2023, then tumbled by 530.55% to -$45.8 million in 2024, then sank by 34.96% to -$61.8 million in 2025.
- Business Quant data shows MNPR's Enterprise Value at -$61.8 million in Q4 2025, -$127.7 million in Q3 2025, and -$39.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Monopar Therapeutics | 800.03 Mn | 738.20 Mn | - | -61.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -61.83 Mn |
| Sep 30, 2025 | -127.68 Mn |
| Jun 30, 2025 | -39.50 Mn |
| Mar 31, 2025 | -39.71 Mn |
| Dec 31, 2024 | -45.82 Mn |
| Sep 30, 2024 | -6.02 Mn |
| Jun 30, 2024 | -6.12 Mn |
| Mar 31, 2024 | -7.81 Mn |
| Dec 31, 2023 | -7.27 Mn |
| Sep 30, 2023 | -5.52 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -10.42 Mn |
| Dec 31, 2022 | -8.19 Mn |
| Sep 30, 2022 | -13.92 Mn |
| Jun 30, 2022 | -16.46 Mn |
| Mar 31, 2022 | -17.82 Mn |
| Dec 31, 2021 | -20.01 Mn |
| Sep 30, 2021 | -21.98 Mn |
| Jun 30, 2021 | -24.29 Mn |
| Mar 31, 2021 | -25.72 Mn |